
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CDC slashes list of recommended childhood vaccinations from 17 to 10
2
Predictions for 2026 from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., and others
3
Predictions for 2026 from Tracy Baroni Allmon, Sharon Faust, Mike Kolodij, and others
4
FDA issues third rejection of bevacizumab to treat wet AMD
5






















































